

Press release

Ingelise Saunders appointed CEO of SLS Invest

Ingelise Saunders has been appointed CEO of SLS Invest. She succeeds Per Carendi who after 4 years as CEO has decided to retire.

STOCKHOLM, September 5, 2011

Ingelise Saunders previous positions include CEO of ACE BioSciences and CEO of Celltech Pharmaceuticals Ltd in UK. Prior to this, she held a number of executive management positions during her 15 years at NovoNordisk A/S. Ingelise Saunders is currently CEO of Action Pharma A/S, one of SLS Invest's portfolio companies, and serves on the board of directors of Topotarget A/S..

Lars Ingelmark, Chairman of SLS Invest, comments:

"SLS Invest has successfully converted into an evergreen structure with a portfolio consisting of a number of companies with high medical – and hence commercial – potential. Going forward, Ingelise Saunders has the right profile for the role as CEO of SLS Invest. Her vast experience and proven ability to develop early stage companies into commercial businesses will be of great value as we continue to create value in our existing portfolio".

Ingelise Saunders, appointed CEO of SLS Invest, comments:

"SLS Invest has a portfolio with a number of companies with products on the market. Going forward, the main challenge is building these into successful, cash generating companies. Throughout my career, I have worked with shaping products for the market, and I have been involved in building businesses through organic growth as well as M&A's, partnering and licensing agreements. I look forward to use my knowledge and experience as active owner in SLS Invest's portfolio companies and to create shareholder value".

For further information, please contact:

Lars Ingelmark, Chairman of the board, SLS Invest

Phone: +46 31 741 1035, +46 708 741 035, e-mail: lars.ingelmark@apfond6.se

Ingelise Saunders, CEO, SLS Invest

Phone: +45 2020 3687, e-mail: insa@slsinvest.com

About SLS Invest

SLS Invest AB is a Scandinavian investment company with offices in Stockholm and Copenhagen. We focus on Life Sciences and operate as an evergreen structure, seeking significant ownership stakes in companies with a proven business model and innovative products addressing a significant medical need. We prefer late stage investments and our focus will be in Medtech. Our current portfolio is in late stage development phase or in commercialization phase. Assets under management are some M€ 160. The majority of our portfolio companies have products on the market with significant and rapidly growing revenues. www.slsinvest.com